Key statistics
As of last trade Adlai Nortye Ltd (N2U0:FRA) traded at 10.90, -17.42% below its 52-week high of 13.20, set on Apr 30, 2024.
52-week range
Open | 0.00 |
---|---|
High | 10.90 |
Low | 10.90 |
Bid | 1.72 |
Offer | 1.85 |
Previous close | 10.90 |
Average volume | -- |
---|---|
Shares outstanding | 12.30m |
Free float | 6.32m |
P/E (TTM) | -- |
Market cap | 72.69m USD |
EPS (TTM) | -6.21 USD |
Data delayed at least 15 minutes, as of May 24 2024 14:29 BST.
More ▼
Announcements
- Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
- Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
- Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
- Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
- Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
- Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
- Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
More ▼